Associated Genetic Biomarkers
Topoisomerase (DNA) II alpha (TOP2A) is a gene that encodes a protein that controls and alters topologic states of DNA during transcription. Missense mutations, synonymous mutations, frameshift deletions, nonsense mutations, and frameshift insertions are observed in cancers such as colon cancer, skin cancer, and endometrial cancer.
TOP2A is altered in 0.35% of all cancers.
The most common alteration in TOP2A is TOP2A Amplification (0.02%) .
TOP2A status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains TOP2A status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with TOP2A status in the inclusion eligibility criteria most commonly target breast carcinoma .
Significance of TOP2A in Diseases
Breast Carcinoma +
TOP2A is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TOP2A status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.